A Covid-19 lawsuit, a heart attack treatment developed using spider venom and a collaboration to fight antimicrobial resistance (AMR) are some of the theme’s of this week’s news round-up.
News round-up by DDW’s Reece Armstrong for 4 – 8 July.
Biopharmaceutical company CureVac has filed a lawsuit against BioNTech SE and two of its subsidiaries in relation to an alleged infringement of the company’s portfolio used in the manufacture and sale of the Comirnaty Covid-19 vaccine.
A new joint-venture has been formed between Evotec, Boehringer Ingelheim and bioMérieux in a bid to fight antimicrobial resistance (AMR) through the development of new antimicrobials and diagnostics.
A drug candidate for heart attacks which contains venom from a deadly spider has moved closer to clinical trials due to investment of $23 million.
GSK has completed its acquisition of the biopharmaceutical company Sierra Oncology, boosting its portfolio of oncology medicines.
The burden of chronic kidney disease (CKD) in adult populations has found to be greater than previously estimated, according to the latest real-world evidence study.